文献速递妇科生殖医学

多囊卵巢综合征女性长期心脏代谢疾病风险:系统综述与荟萃分析

Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis.
PubMed 文献 · Hum Reprod Update · 2020-01-01

该系统综述与荟萃分析纳入23项队列研究,比较≥18岁PCOS女性与非PCOS女性的心脏代谢结局。PCOS女性高血压风险RR 1.75、2型糖尿病风险RR 3.00、非致死性脑血管事件风险RR 1.41均升高,总胆固醇较高而高密度脂蛋白胆固醇较低。

要点

  • PCOS女性2型糖尿病风险显著升高(RR 3.00)。
  • PCOS女性高血压风险升高(RR 1.75)。
  • PCOS女性非致死性脑血管事件风险升高(RR 1.41)。

核心结论

  • PCOS女性心脏代谢疾病风险增加,该风险量化有助于临床心血管风险评估。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE和EMBASE自建库至2019年9月,最终纳入23项队列研究。

主要发现

  • PCOS女性高血压风险RR 1.75(95%CI 1.42-2.15)。
  • PCOS女性2型糖尿病风险RR 3.00(95%CI 2.56-3.51)。
  • PCOS女性总胆固醇MD 7.14 mg/dl(95%CI 1.58-12.70)。
  • PCOS女性高密度脂蛋白胆固醇MD -2.45 mg/dl(95%CI -4.51至-0.38)。
  • PCOS女性非致死性脑血管事件风险RR 1.41(95%CI 1.02-1.94)。

关键数值与推荐

  • 低密度脂蛋白胆固醇MD 3.32 mg/dl(95%CI -4.11-10.75)无显著差异。
  • 甘油三酯MD 18.53 mg/dl(95%CI -0.58-37.64)无显著差异。
  • 冠心病事件RR 1.78(95%CI 0.99-3.23)无显著差异。
  • 致死性心血管事件因死亡率数据缺乏未能进行荟萃分析。

临床怎么用

  • 临床医生应告知PCOS女性心脏代谢疾病风险增加,并在心血管风险评估中加以考虑。

局限性

  • 致死性心血管事件因死亡率数据缺乏未能进行荟萃分析。
  • 需要未来临床试验评估心脏代谢筛查和管理能否降低PCOS女性心血管疾病发病率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polycystic ovary syndrome (PCOS) is associated with cardiometabolic disease, but recent systematic reviews and meta-analyses of longitudinal studies that quantify these associations are lacking. OBJECTIVE AND RATIONALE: Is PCOS a risk factor for cardiometabolic disease? SEARCH METHODS: We searched from inception to September 2019 in MEDLINE and EMBASE using controlled terms (e.g. MESH) and text words for PCOS and cardiometabolic outcomes, including cardiovascular disease (CVD), stroke, myocardial infarction, hypertension (HT), type 2 diabetes (T2D), metabolic syndrome and dyslipidaemia. Cohort studies and case-control studies comparing the prevalence of T2D, HT, fatal or non-fatal CVD and/or lipid concentrations of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TGs) between women with and without PCOS of ≥18 years of age were eligible for this systematic review and meta-analysis. Studies were eligible regardless of the degree to which they adjusted for confounders including obesity. Articles had to be written in English, German or Dutch. Intervention studies, animal studies, conference abstracts, studies with a follow-up duration less than 3 years and studies with less than 10 PCOS cases were excluded. Study selection, quality assessment (Newcastle-Ottawa Scale) and data extraction were performed by two independent researchers. OUTCOMES: Of the 5971 identified records, 23 cohort studies were included in the current systematic review. Women with PCOS had increased risks of HT (risk ratio (RR): 1.75, 95% CI 1.42 to 2.15), T2D (RR: 3.00, 95% CI 2.56 to 3.51), a higher serum concentration of TC (mean difference (MD): 7.14 95% CI 1.58 to 12.70 mg/dl), a lower serum concentration of HDL-C (MD: -2.45 95% CI -4.51 to -0.38 mg/dl) and increased risks of non-fatal cerebrovascular disease events (RR: 1.41, 95% CI 1.02 to 1.94) compared to women without PCOS. No differences were found for LDL-C (MD: 3.32 95% CI -4.11 to 10.75 mg/dl), TG (MD 18.53 95% CI -0.58 to 37.64 mg/dl) or coronary disease events (RR: 1.78, 95% CI 0.99 to 3.23). No meta-analyses could be performed for fatal CVD events due to the paucity of mortality data. WIDER IMPLICATIONS: Women with PCOS are at increased risk of cardiometabolic disease. This review quantifies this risk, which is important for clinicians to inform patients and to take into account in the cardiovascular risk assessment of women with PCOS. Future clinical trials are needed to assess the ability of cardiometabolic screening and management in women with PCOS to reduce future CVD morbidity.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Wekker V, van Dammen L, Koning A, et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020. PMID: 32995872. doi:10.1093/humupd/dmaa029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。